Publication:
Age and survival of cervical cancer patients with bone metastasis

dc.contributor.authorAdisak Nartthanarungen_US
dc.contributor.authorKamolrat Thanapprapasren_US
dc.contributor.authorUmaporn Udomsubpayakulen_US
dc.contributor.authorDuangmani Thanapprapasren_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherThailand National Metal and Materials Technology Centeren_US
dc.contributor.otherSamitivej Hospital (Sukhumvit)en_US
dc.date.accessioned2018-11-09T02:00:09Z
dc.date.available2018-11-09T02:00:09Z
dc.date.issued2014-01-01en_US
dc.description.abstractBackground: To determine survival times of cervical cancer patients with bone metastasis related to the effect of age at the time of cervical cancer diagnosis, we performed the retrospectively analytical study. Methods: A total of 68 cervical cancer patients with bone metastasis were treated at a single hospital, during January 1998 to December 2010. Fifty-two medical records were identified and collected, the remaining sixteen medical records were not found. Main outcome measures were patient characteristics, clinical information, duration from cervical cancer diagnosis to bone metastasis diagnosis, survival time after bone metastasis and overall survival time. Results: Among fifty-two cervical cancer patients with bone metastasis, there were 13 patients who were less than 45 years old, and 39 patients were 45 years old or more at the time of cervical cancer diagnosis. The younger group had less median overall survival than the older group, with a statistically significant difference (21 months, 95% CI 19.93-22.06; 34 months, 95% CI 23.27-44.72, p = 0.021). However, they were comparable in the duration from cervical cancer diagnosis to bone metastasis diagnosis and the survival time after bone metastasis. Conclusion: Young patients with bone metastasis aged less than 45 years old at the time of cervical cancer diagnosis have a poorer prognosis than the elderly patients. Impact: To improve survival and quality of life, more intensive and novel multimodal treatments at the time of cervical cancer diagnosis should be considered in patients less than forty-five years, who can tolerate the side effects better.en_US
dc.identifier.citationAsian Pacific Journal of Cancer Prevention. Vol.15, No.19 (2014), 8401-8404en_US
dc.identifier.doi10.7314/APJCP.2014.15.19.8401en_US
dc.identifier.issn15137368en_US
dc.identifier.other2-s2.0-84930714633en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/33479
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84930714633&origin=inwarden_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.subjectMedicineen_US
dc.titleAge and survival of cervical cancer patients with bone metastasisen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84930714633&origin=inwarden_US

Files

Collections